熱門資訊> 正文

拜耳公司其眼部疾病治疗方法在中国获得批准

2025-05-22 21:40

再生元製藥公司(REGN) 0
奧瑞許科技(OSUR) 0

Bayer A.G. (OTCPK:BAYZF) said on Thursday that China’s National Medical Products Administration has approved Eylea 8 mg for age-related macular degeneration treatment.
The Eylea 8 mg is being jointly developed by Bayer and Regeneron (NASDAQ:REGN).
The approval is based on positive results from the late-stage trial at week 48, which demonstrated comparable efficacy and safety of Eylea 8 mg with treatment intervals of 3 or 4 months.

More on Regeneron Pharmaceuticals, Bayer

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Bayer Stock Investment Could Pay Off, But It Is Not For The Faint Of Heart
RFK Jr.'s MAHA report to target vaccine scheduling, food chemicals - report
OraSure rises as seen benefitting from 23andMe/Regeneron deal

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。